Cargando…

Engineering CAR-T cells

Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors. CAR-T cells are generated by the T cells from patients’ or donors’ blood. After the T c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Cheng, Liu, Jun, Zhong, Jiang F., Zhang, Xi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5482931/ https://www.ncbi.nlm.nih.gov/pubmed/28652918 http://dx.doi.org/10.1186/s40364-017-0102-y

Ejemplares similares

Recent advances in CAR-T cell engineering
por: Huang, Ruihao, et al.
Publicado: (2020)

Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
por: Liu, Jun, et al.
Publicado: (2017)

CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
por: Arjomandnejad, Motahareh, et al.
Publicado: (2022)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

Engineering CAR T cells for enhanced efficacy and safety
por: Wu, Yiqian, et al.
Publicado: (2022)

Cutting-Edge CAR Engineering: Beyond T Cells
por: Chocarro, Luisa, et al.
Publicado: (2022)

Engineering Next-Generation CAR-T Cells for Better Toxicity Management
por: Andrea, Alain E., et al.
Publicado: (2020)

How Can We Engineer CAR T Cells to Overcome Resistance?
por: Glover, Maya, et al.
Publicado: (2021)

CAR T cells: engineered immune cells to treat brain cancers and beyond
por: Huang, Zoufang, et al.
Publicado: (2023)

Multipurposing CARs: Same engine, different vehicles
por: Hossian, A.K.M. Nawshad, et al.
Publicado: (2022)

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
por: Koristka, Stefanie, et al.
Publicado: (2019)

Engineering strategies to overcome the current roadblocks in CAR T cell therapy
por: Rafiq, Sarwish, et al.
Publicado: (2019)

Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents
por: Park, Chi Hoon
Publicado: (2021)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

Current Progress in CAR-T Cell Therapy for Solid Tumors
por: Ma, Shuo, et al.
Publicado: (2019)

Strategies to enhance CAR-T persistence
por: Liu, Yue, et al.
Publicado: (2022)

Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies
por: Mangal, Joslyn L., et al.
Publicado: (2021)

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
por: Dimitri, Alexander, et al.
Publicado: (2022)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
por: Wu, Xinyu, et al.
Publicado: (2022)

Engineering CAR T Cells to Target the HIV Reservoir
por: Mu, Wenli, et al.
Publicado: (2020)

Combating challenges in CAR-T cells with engineering immunology
por: Wang, Clement Yisai, et al.
Publicado: (2022)

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing
por: Castellanos-Rueda, Rocío, et al.
Publicado: (2022)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy
por: Zhang, Xi-Wen, et al.
Publicado: (2023)

CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
por: Marofi, Faroogh, et al.
Publicado: (2021)

Intelligent tunable CAR-T cell therapy leads the new trend
por: Cheng, Jiayi, et al.
Publicado: (2023)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
por: Qu, Chunrun, et al.
Publicado: (2022)

Activation-inducible CAR expression enables precise control over engineered CAR T cell function
por: Fraessle, Simon P., et al.
Publicado: (2023)

Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two cases report
por: Zhang, Cheng, et al.
Publicado: (2019)

Engineering light-controllable CAR T cells for cancer immunotherapy
por: Huang, Ziliang, et al.
Publicado: (2020)

Engineering enhanced CAR T-cells for improved cancer therapy
por: Milone, Michael C., et al.
Publicado: (2021)

New Strategies for the Treatment of Solid Tumors with CAR-T Cells
por: Zhang, Hao, et al.
Publicado: (2016)

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
por: Gong, Ying, et al.
Publicado: (2021)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

CAR‐T therapy: Prospects in targeting cancer stem cells
por: Cui, Xiaoyue, et al.
Publicado: (2021)

Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function
por: Salzer, Benjamin, et al.
Publicado: (2020)

The Enigmatic Nature of the TCR-pMHC Interaction: Implications for CAR-T and TCR-T Engineering
por: Shevyrev, D. V., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bd2k2b3vm7ueshffud3pqm5l9c